Search results
Results from the WOW.Com Content Network
Acute cutaneous lupus erythematosus is a cutaneous condition characterized by a bilateral malar rash (also known as a "butterfly rash") and lesions that tend to be transient, and that follow sun exposure. [1] The acute form is distinct from chronic and subacute cutaneous lupus erythematosus, which may have different types of skin lesions. [2]
Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]
The three main categories of lesions are chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus. People with discoid lupus may exhibit thick, red scaly patches on the skin. Similarly, subacute cutaneous lupus manifests as red, scaly patches of skin but with distinct edges. Acute cutaneous lupus manifests as a rash.
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
Lupus is a chronic disease that can cause inflammation and pain in any part of the body. The disease impacts about 1.5 million Americans, but women are nine times more likely to develop lupus than ...
Severe cutaneous adverse reactions (SCARs) are a group of potentially lethal adverse drug reactions that involve the skin and mucous membranes of various body openings such as the eyes, ears, and inside the nose, mouth, and lips. In more severe cases, SCARs also involves serious damage to internal organs. SCARs includes five syndromes:
Tetracyclines are generally used in the treatment of infections of the urinary tract, respiratory tract, and the intestines and are also used in the treatment of chlamydia, especially in patients allergic to β-lactams and macrolides; however, their use for these indications is less popular than it once was due to widespread development of resistance in the causative organisms.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at ...